Mangrove Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Mangrove Partners’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$993K	Buy	12,918 +2,331	+22%	+$182K	0.08%	114
2025 Q4	$836K	Buy	+10,587	New	+$917K	0.07%	130
2020 Q2	–	Sell	-426,162	Closed	-$17.4M	–	54
2020 Q1	$17.4M	Buy	426,162 +99,384	+30%	+$5.29M	2.39%	12
2019 Q4	$20.2M	Sell	326,778 -183,174	-36%	-$12.1M	2.95%	11
2019 Q3	$37.2M	Sell	509,952 -39,449	-7%	-$2.95M	4.5%	6
2019 Q2	$45.2M	Hold	549,401	–	–	5.11%	5
2019 Q1	$38.8M	Hold	549,401	–	–	5.18%	5
2018 Q4	$24.7M	Buy	549,401 +37,000	+7%	+$1.94M	3.29%	8
2018 Q3	$29M	Buy	512,401 +115,478	+29%	+$7.07M	1.83%	8
2018 Q2	$26.5M	Buy	396,923 +20,609	+5%	+$1.29M	1.71%	10
2018 Q1	$21.9M	Hold	376,314	–	–	1.43%	12
2017 Q4	$24.3M	Hold	376,314	–	–	3.27%	12
2017 Q3	$19.8M	Buy	376,314 +96,448	+34%	+$4.6M	3.39%	11
2017 Q2	$13.1M	Buy	279,866 +221,491	+379%	+$10.7M	2.67%	12
2017 Q1	$2.89M	Buy	+58,375	New	+$3.28M	0.66%	18

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners's ANIP Position: Q1 2026 in Review

Mangrove Partners increased its ANI Pharmaceuticals (ANIP) stake by 22% in Q1 2026, buying an estimated $182K and bringing the position to 12,918 shares worth $993K. The position accounts for 0.08% of the portfolio, ranked #114.

Mangrove Partners first reported a position in ANIP in Q1 2017 and has held it in 15 quarters since. The position peaked at $45.2M in Q2 2019. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

Mangrove Partners held 12,918 shares of ANI Pharmaceuticals worth $993K as of Q1 2026.
Mangrove Partners bought 2,331 ANI Pharmaceuticals shares in Q1 2026, an estimated $182K.
ANI Pharmaceuticals made up 0.08% of Mangrove Partners's portfolio in Q1 2026, its #114 holding.
Mangrove Partners first reported a position in ANI Pharmaceuticals in Q1 2017 and has held it in 15 quarters since.
Mangrove Partners's ANI Pharmaceuticals position peaked at $45.2M in Q2 2019.
280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.